Table 3. Summary of case series and cohort studies describing response of HIV-1/2 dual-infected patients on ART in the HAART era. Individual case reports excluded, but are discussed in the main text.

Sichuan has confirmed its first-ever case of HIV-2 infection, a rare strain of the virus seldom seen in China, health ...

Some HIV-1 carriers who have received an early antiretroviral treatment during several years are able to control the virus for a long term after treatment interruption. However, the mechanisms ...

In a recent study published in the Advanced Science journal, researchers assessed the effectiveness of synthetic mucin gels in the inhibition of human immunodeficiency virus-1 (HIV-1) and herpes ...

In a recent study posted to Research Square* preprint server, researchers assessed the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV envelope (E) proteins on ...

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is ...

Nearly 37.7 million people globally are living with HIV, with 1.2 million residing in the US 1,2. Of those individuals, 13 in 100 in the US and 16 in 100 globally are unaware of their diagnosis 1,2.

Two more patients were announced functionally "cured" of HIV during AIDS 2022. One male patient underwent a bone marrow transplant from a donor who is HIV immune. The other person, a woman, has an ...